Physician profile
Wing C Chau
NPI 1518065630
$1,899.73
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,319 · 2021: $351 · 2022: $230.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $188.22 | 2019 | |
| Janssen Pharmaceuticals, INC | $186.83 | 2019 | |
| Amgen INC. | $156.87 | 2019 | |
| Novo Nordisk INC | $119.89 | 2019 | |
| Genentech USA, INC. | $119.57 | 2019 | |
| Daiichi Sankyo INC. | $115.10 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $113.14 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $108.82 | 2022 | |
| Amarin Pharma, INC. | $106.28 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $91.56 | 2019 | |
| Grt US Holding, INC. | $90.00 | 2021-2022 | |
| Sanofi Pasteur INC. | $82.95 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $78.02 | 2019 | |
| Biodelivery Sciences International, INC. | $76.42 | 2021 | |
| Lilly USA, LLC | $73.55 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $70.50 | 2021 | |
| Emergent Biosolutions INC. | $45.00 | 2021 | |
| Abbvie INC. | $35.79 | 2021 | |
| Impel Pharmaceuticals INC. | $22.53 | 2022 | |
| Baudax Bio INC. | $18.69 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wing Chau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.